Introduction: We assessed clinical and urodynamic effects of solifenacin versus mirabegron in women with overactive bladder (OAB) syndrome. Material and Methods: Eighty women with OAB were randomized into 2 groups. In group A, the patients received solifenacin 5 mg once a day for 12 weeks; in group B, the patients received mirabegron 50 mg once a day for 12 weeks. Symptoms were assessed with OAB Symptom Score (OABSS). Patients underwent urodynamic investigation with pressure flow study. OABSS and urodynamic study were performed before and after treatment. Results: Both solifenacin and mirabegron were effective in improving OAB symptoms. Mirabegron showed greater tolerability with fewer patients discontinuing therapy because of side effects. Both solifenacin and mirabegron were effective in improving the storage function in the pressure flow study, but solifenacin showed a significant reduction of the detrusor pressure in the voiding phase with an increase in the postvoid residual urine volume. Conclusions: Mirabegron has shown to be a drug with the better balance between efficacy and tolerability in women with OAB.

Keywords:
Overactive bladder syndrome, Antimuscarinic, Urodynamic study, Solifenacin, Mirabegron
1.
Abrams P, Cardozo L, Fall M, et al: The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn 2002;21:167-178.
2.
Irwin DE, Milsom I, Hunskaar S, et al: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of EPIC study. Eur Urol 2006;50:1306-1314; discussion 1314-1315.
3.
Camões J, Coelho A, Castro-Diaz D, Cruz F: Lower urinary tract symptoms and aging: the impact of chronic bladder ischemia on overactive bladder syndrome. Urol Int 2015;95:373-379.
4.
Stewart WF, Van Rooyen JB, Cundiff GW, et al: Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-336.
5.
Irwin DE, Abrams P, Milsom I, Kopp Z, Reilly K: Understanding the elements of overactive bladder: questions raised by the EPIC study. BJU Int 2008;101:1381-1387.
6.
Madhu C, Enki D, Drake MJ, Hashim H: The functional effects of cigarette smoking in women on the lower urinary tract. Urol Int 2015;95:478-482.
7.
Apostolidis A: Antimuscarinics in the treatment of OAB: is there a first-line and a second-line choice? Curr Drug Targets 2015;16:1187-1197.
8.
Vecchioli-Scaldazza C, Morosetti C, Berouz A, Giannubilo W, Ferrara V: Solifenacin succinate versus percutaneous tibial nerve stimulation in women with overactive bladder syndrome: results of a randomized controlled crossover study. Gynecol Obstet Invest 2013;75:230-234.
9.
Maniscalco M, Singh-Franco D, Wolowich WR, et al: Solifenacin succinate for the treatment of symptoms of overactive bladder. Clin Ther 2006;28:1247-1272.
10.
Chapple CR, Rechberger T, Al-Shukri S, et al: Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004;93:303-310.
11.
Yamaguchi O, Marui E, Kakizaki H, et al: Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int 2007;100:579-587.
12.
Matsukawa Y, Takai S, Funahashi Y, Yamamoto T, Gotoh M: Urodynamic evaluation of the efficacy of mirabegron on storage and voiding functions in women with overactive bladder. Urology 2015;85:786-790.
13.
Homma Y, Yoshida M, Seki N, et al: Symptom assessment tool for overactive bladder syndrome - overactive bladder symptom score. Urology 2006;68:318-323.
14.
Kosilov K, Loparev S, Ivanovskaya M, Kosilova L: A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron. Arch Gerontol Geriatr 2015;61:212-216.
15.
Kaidoh K, Igawa Y, Takeda H, Yamazaki Y, et al: Effects of selective beta2 and beta3-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infarcted rats. J Urol 2002;168:1247-1252.
16.
Takeda H, Yamazaki Y, Igawa Y, et al: Effects of beta(3)-adrenoceptor stimulation on prostaglandin E(2)-induced bladder hyperactivity and on the cardiovascular system in conscious rats. Neurourol Urodyn 2002;21:558-565.
17.
Woods M, Carson N, Norton NW, Sheldon JH, Argentieri TM: Efficacy of the beta3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat. J Urol 2001;166:1142-1147.
18.
Tyagi P, Tyagi V: Mirabegron, a beta3-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder. IDrugs 2010;13:713-722.
19.
Hatanaka T, Ukai M, Watanabe M, et al: Effect of mirabegron, a novel β3-adrenoceptor agonist, on bladder function during storage phase in rats. Naunyn Schmiedebergs Arch Pharmacol 2013;386:71-78.
20.
Tanaka Y, Masumori N, Tsukamoto T: Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder. Int J Urol 2010;17:796-800.
21.
Ronchi P, Gravina GL, Galatioto GP, Costa AM, Martella O, Vicentini C: Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity. Neurourol Urodyn 2009;28:52-57.
22.
Hsiao SM, Chang TC, Wu WY, Chen CH, Yu HJ, Lin HH: Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. J Obstet Gynaecol Res 2011;37:1084-1091.
23.
Nitti VW, Rosenberg S, Mitcheson DH, et al: Urodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol 2013;190:1320-1327.
24.
Osman NI, Chapple CR, Abrams P, et al: Detrusor underactivity and the underactive bladder: a new clinical entity? A review of current terminology, definitions, epidemiology, aetiology, and diagnosis. Eur Urol 2014;65:389-398.
25.
Defreitas GA, Zimmern PE, Lemack GE, Shariat SF: Refining diagnosis of anatomic female bladder outlet obstruction: comparison of pressure-flow study parameters in clinically obstructed women with those of normal controls. Urology 2004;64:675-679; discussion 679-681.
26.
Maman K, Aballea S, Nazir J, et al: Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol 2014;65:755-765.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.